Iktos announces strategic collaboration with Cube biotech

Iktos formed a strategic partnership with Cube Biotech, announced January 13, 2025, to combine their technologies in drug discovery. The goal is to "develop novel small molecule agonists of the Amylin Receptor — a target with transformative potential for addressing obesity, diabetes, and other cardiometabolic disorders." The collaboration pairs Cube Biotech's membrane protein technology with Iktos' AI-driven drug discovery platform to create new therapeutic compounds targeting the Amylin Receptor. No deal terms or financial figures are disclosed in the announcement.

Iktos is a generative-AI drug-design company whose de novo molecule-design platform is used directly by partner pharma companies' medicinal chemists.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.